Oculis gains on FDA breakthrough therapy status for optic neuritis therapy

 

• Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis
  
  

• Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S.
  
  

• Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY trial

https://finance.yahoo.com/news/oculis-announces-u-fda-breakthrough-090000709.html